Neuro-Oncology

Published by: Oxford University Press  

People

  1. Haque
    Haque
  2. Kramer
    Kramer
  3. Dunkel
    Dunkel
  4. Khakoo
    Khakoo
  5. Donzelli
    Donzelli
  6. Souweidane
    Souweidane
  7. Karajannis
    Karajannis
  8. Greenfield
    Greenfield
  9. Wolden
    Wolden
  10. Cheung
    Cheung

Groups

  1. Neuro-Oncology Service (34)
  2. Neuroradiology Service (34)
  3. Pediatrics, Department of (34)
  4. Radiology, Department of (34)
  5. Survivorship Research (27)
  6. Advanced Practice Providers (19)
  7. Nursing (19)
  8. Tow Center for Developmental Oncology (TCDO) (15)
  9. GSK Faculty (14)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (13)
Search Within
  1. "Sofia Haque"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (4)
Groups
  1. Neuro-Oncology Service (34)
  2. Neuroradiology Service (34)
  3. Pediatrics, Department of (34)
  4. Radiology, Department of (34)
  5. Survivorship Research (27)
  6. Advanced Practice Providers (19)

More Groups

People
  1. Sofia Haque (34)
  2. Kim Kramer (18)
  3. Ira Dunkel (17)
  4. Yasmin Khakoo (17)
  5. Maria Donzelli (16)
  6. Mark Souweidane (15)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (5)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publishers
  1. Oxford University Press (34)

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma
    Journal Article

    Souweidane, M. M.; Bander, E. D.; Zanzonico, P.; Reiner, A. S.; Manino, N.; Haque, S.; Carrasquillo, J. A.; Lyashchenko, S. K.; Thakur, S. B.; Lewis, J. S.; more...
    Neuro-Oncology (2025)

    Fulltext@MSK | Save
  • Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: A Children’s Oncology Group study
    Journal Article

    Karajannis, M. A.; Onar-Thomas, A.; Lin, T.; Baxter, P. A.; Boué, D. R.; Cole, B. L.; Fuller, C.; Haque, S.; Jabado, N.; Lucas, J. T. Jr; more...
    Neuro-Oncology (2025)

    Fulltext@MSK | Save
  • Phase 1 dose finding study evaluating the safety, tolerability, and efficacy of iopofosine I 131 in children, adolescents, and young adults with inoperable relapsed or refractory high-grade gliomas: A trial-in-progress
    Meeting Abstract

    Sait, S. F.; Morgenstern, D. A.; Pandit-Taskar, N.; Das, A.; Pudel, M.; Fisher, C.; Zanzonico, P.; Haque, S.; Longcor, J.; Shustov, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Minimally-invasive molecular diagnosis of infiltrating brainstem gliomas through cerebrospinal fluid cell-free DNA sequencing
    Meeting Abstract

    Hill, K.; Giantini-Larsen, A.; Hickman, R. A.; Holle, B. M.; Ucpinar, B. A.; Alano, T.; Doe-Tetteh, S.; DiNapoli, S.; Riviere-Cazaux, C.; Burns, T. C.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Non-invasive diagnosis of brainstem gliomas in pediatric, adolescent, and young adult patients through cerebrospinal fluid cell-free DNA sequencing
    Meeting Abstract

    Hill, K.; Giantini-Larsen, A.; Hickman, R. A.; Holle, B.; Alano, T.; Doe-Tetteh, S.; Bouvier, N.; Li, S.; Stockfisch, E.; Huereca, C.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients
    Journal Article

    Miller, A. M.; Szalontay, L.; Bouvier, N.; Hill, K.; Ahmad, H.; Rafailov, J.; Lee, A. J.; Rodriguez-Sanchez, M. I.; Yildirim, O.; Patel, A.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Noninvasive diagnosis of gliomas through CSF CFDNA sequencing in pediatric and adolescent and young adult (AYA) patients
    Meeting Abstract

    Hill, K.; Miller, A. M.; Li, B. K.; Bouvier, N.; Li, S.; Alano, T.; Doe-Tetteh, S.; Huereca, C.; DiNapoli, S.; Lee, A.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG)
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Tasker, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Dunkel, I. J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Phase 2 study of veliparib and local irradiation, followed by maintenance veliparib and temozolomide, in patients with newly diagnosed highgrade glioma without H3 K27M or BRAF Mutations: A report from the Children's Oncology Group ACNS1721 study
    Meeting Abstract

    Karajannis, M.; Onar-Thomas, A.; Baxter, P.; Butingan, N.; Fuller, C.; Gajjar, A.; Haque, S.; Jabado, N.; Lin, T.; Lucas, J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Neurocutaneous melanocytosis-associated hydrocephalus: The MSK experience from 2001-2022
    Meeting Abstract

    Rodriguez, S.; Sener, U.; Elmore, K.; Haque, S.; Suser, S.; Greenfield, J.; Donzelli, M.; DePass, C.; Pugh, J.; Porter, J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save

    • Neuro-Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-oncology 15235866 Unknown
    Neuro-Oncology 15228517 The Author(s) 2024
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 The Author(s)
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1522-8517 Carden Jennings Publ Co Ltd
    Neuro-Oncology 1522-8517 Duke University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 Unknown
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 The Author(s) 2023
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-oncology 15235866 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1522-8517 Duke University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15235866 Elsevier B.V.
    Neuro-Oncology 1522-8517 Society for Neuro Oncology